Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
758.250.06%
QQQ
708.70-
BTC/USD
77084.291.5296%
DIA
520.800.01%
GLD
396.180.05%
TLT
80.750.04%

Spyre Therapeutics Inc

SYRENASDAQ
Trade with Public
Trade with Public
$88.71
1.782.05%
At close: Sep 10, 5:00 PM EST
$88.71
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Spyre Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Spyre Therapeutics (SYRE).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

1S.Buy
14Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$99Upside to Avg. PT+11.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026WedbushDavid NierengartenMaintainedOutperform$123
Sep 8, 2026BTIGJulian HarrisonMaintainedBuy$121
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and maintains $123 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.
Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $135 to $127.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $130 to $123.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $132 to $121.
Benzinga Newsdesk

Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downgrades on analyst ratings page.
Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved